1. Home
  2. BMHL vs TNXP Comparison

BMHL vs TNXP Comparison

Compare BMHL & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bluemount Holdings Limited Class B Ordinary Shares

BMHL

Bluemount Holdings Limited Class B Ordinary Shares

N/A

Current Price

$3.20

Market Cap

86.8M

Sector

N/A

ML Signal

N/A

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

N/A

Current Price

$5.12

Market Cap

88.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BMHL
TNXP
Founded
2016
2007
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
86.8M
88.0M
IPO Year
2024
2008

Fundamental Metrics

Financial Performance
Metric
BMHL
TNXP
Price
$3.20
$5.12
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $39.00
AVG Volume (30 Days)
4.4K
★ 1.0M
Earning Date
03-30-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 91.75
EPS
★ N/A
N/A
Revenue
N/A
★ $13,107,000.00
Revenue This Year
N/A
$325.44
Revenue Next Year
N/A
$99.29
P/E Ratio
$66.66
★ N/A
Revenue Growth
N/A
★ 29.85
52 Week Low
$3.00
$4.96
52 Week High
$6.35
$20.56

Technical Indicators

Market Signals
Indicator
BMHL
TNXP
Relative Strength Index (RSI) 30.69 18.59
Support Level N/A N/A
Resistance Level $3.87 $12.99
Average True Range (ATR) 0.22 0.41
MACD 0.04 0.12
Stochastic Oscillator 30.00 10.51

Price Performance

Historical Comparison
BMHL
TNXP

About BMHL Bluemount Holdings Limited Class B Ordinary Shares

Bluemount Holdings Ltd through its operating subsidiaries, is a Hong Kong-based consulting and advisory, financial services, and luxury timepiece trading provider. The Company provides consulting and advisory services on business development strategies, including seeking suitable transaction projects for business development or diversification and suitable business partners or investors for fund-raising projects. Its services are centered around three core offerings: Business Transformation, Strategy, and Transactions. The Company also sources, buys, and sells brand-new luxury branded timepieces. It operates through two reportable segments: security-related services and asset management, and trading of timepieces, with the trading of timepieces generating maximum revenue.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

Share on Social Networks: